Bone/Mineral Metabolism

Top Story

Bone loss remains elevated 5 years after RYGB vs. sleeve gastrectomy

Bone loss remains elevated 5 years after RYGB vs. sleeve gastrectomy
November 21, 2017

Adults with uncontrolled type 2 diabetes and obesity treated with Roux-en-Y gastric bypass surgery vs. sleeve gastrectomy or intensive medical therapy had elevated bone turnover markers 5 years later, study data show.

Sangeeta Kashyap, MD, of the department of endocrinology, diabetes and metabolism at Cleveland Clinic, and colleagues evaluated data from the STAMPEDE trial on 95 adults (mean age, 48.5 years) with uncontrolled type 2 diabetes and obesity (mean BMI, 36.5 kg/m2) randomly assigned to intensive medical therapy (n = 25), Roux-en-Y gastric bypass (RYGB; n = 37) or sleeve gastrectomy (n = 33) to determine the 5-year outcomes on bone turnover.

In the Journals PlusPerspective

Eating yogurt plus more fruits, vegetables reduces hip fracture risk in women

November 13, 2017
Women who consumed a large amount of milk but little fruits and vegetables had a higher risk for hip fracture than those who consumed large amounts of fermented milk…
In the Journals PlusPerspective

Air pollution may increase osteoporosis-related bone fracture risk

November 9, 2017
Adults, particularly those with a low income and aged at least 65 years, have an increased risk for bone fracture and osteoporosis-related loss of bone mineral density…
In the Journals Plus

Vitamin D, calcium supplementation not linked with skeletal muscle strength in young men

November 9, 2017
Skeletal muscle strength and serum testosterone levels in young men were not substantially affected by 6 months of cholecalciferol and/or calcium supplementation…
More Headlines »

The Future of the Lipid Panel: An NLA Expert Discussion

This educational activity is supported by an educational grant from Quest Diagnostics, Inc.

Past-President of the National Lipid Association and Editor-in-Chief of the Journal of Clinical Lipidology, Dr. W…
More »
Meeting News

VIDEO: Women with osteoporosis had reduction in vertebral, nonvertebral fractures with abaloparatide, alendronate

November 8, 2017
More »
Resource Centers



What You Need to Know About Familial Chylomicronemia Syndrome: Pathophysiology, Diagnosis, Management, and the Patient Perspective

This activity is supported by an educational grant from Akcea Therapeutics™ A Subsidiary of Ionis Pharmaceuticals, Inc.
Endorsed by: The National Lipid Association.

Familial chylomicronemia syndrome (FCS) is a rare genetic disease that leads to severe hypertriglyceridemia and…
More »